Management of malignant pleural effusions.
Journal
Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
pubmed:
4
6
2020
medline:
5
1
2021
entrez:
4
6
2020
Statut:
ppublish
Résumé
Malignant pleural effusion (MPE) is a common cause of breathlessness indicative of advanced disease. Treatment approaches focus on relief of breathlessness and optimizing quality of life. A number of recent, high-impact publications give further insight into the advantages of different treatment options. This article provides a summary of the most up-to-date evidence in this area. Recent publications have demonstrated comparable pleurodesis outcomes of talc slurry to talc poudrage and explore strategies to combine the advantages of indwelling pleural catheters (IPCs) with a chemical pleurodesis. A daily IPC drainage regime improves the chances of pleurodesis success and early IPC removal in patients without significant trapped lung. MPE is a diverse condition, with no one strategy representing the 'best' approach for all. Management decisions should be made in conjunction with the patient, taking their views and preferences into consideration.
Identifiants
pubmed: 32487872
doi: 10.1097/MCP.0000000000000685
pii: 00063198-202007000-00005
doi:
Substances chimiques
Talc
14807-96-6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-345Références
Bibby AC, Dorn P, Psallidas I, et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J 2018; 52:1800349.
Clive AO, Jones HE, Bhatnagar R, et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev 2016; 5:CD010529.
Psallidas I, Kanellakis N, Gerry S, et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol 2018; 19:930–939.
Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline. Thorax 2010; 65: (Suppl 2): ii32–ii40.
Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 2014; 69:1098–1104.
Feller-Kopman DJ, Reddy CB, DeCamp MM, et al. Management of malignant pleural effusions: an official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med 2018; 198:839–849.
Lee YC, Baumann MH, Maskell NA, et al. Pleurodesis practice for malignant pleural effusions in five English-speaking countries. Chest 2003; 124:2229–2238.
Bhatnagar R, Piotrowska HE, Laskawiec-Szkonter M, et al. Effect of thoracoscopic talc poudrage vs talc slurry via chest tube on pleurodesis failure rate among patients with malignant pleural effusions. JAMA 2020; 323:60–69.
Yim A, Chan A, Lee T, et al. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996; 62:1655–1658.
Dresler C, Olak J, Herndon J, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127:909–915.
Terra R, Junqueira J, Teixeira L, et al. Is full postpleurodesis lung expansion a determinant of successful outcome after talc pleurodesis? Chest 2009; 136:361–368.
Rahman NM, Pepperell J, Rehal S, et al. Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: the TIME1 randomized clinical trial. JAMA 2015; 314:2641–2653.
Walker S, Mercer R, Maskell N, Rahman NM. Malignant pleural effusion management: keeping the flood gates shut. Lancet Respir Med 2019; pii: S2213-2600(19)30373-X. doi: 10.1016/S2213-2600(19)30373-X.
doi: 10.1016/s2213-2600(19)30373-x
pii: s2213-2600(19)30373-x.
Davies H, Mishra E, Kahan B, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnoea in patients with malignant pleural effusion: the TIME 2 randomized controlled trial. JAMA 2012; 307:2383–2389.
Thomas R, Fysh ET, Smith NA, et al. Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial. JAMA 2017; 318:1903–1912.
Wahidi MM, Reddy C, Yarmus L, et al. Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions: the ASAP trial. Am J Respir Crit Care Med 2017; 195:1050–1057.
Muruganandan S, Azzopardi M, Fitzgerald DB, et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med 2018; 6:671–680.
Bhatnagar R, Keenan EK, Morley AJ, et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion. N Engl J Med 2018; 378:1313–1322.
Sivakumar P, Douiri A, West A, et al. OPTIMUM: a protocol for a multicentre randomised controlled trial comparing outpatient talc slurry via indwelling pleural catheter for malignant pleural effusion vs usual inpatient management. BMJ Open 2016; 6:e012795.
Kaur Pannu J, Lentz R. Discordance between pleural eslastance and postthoracentesis chest radiograph: putting pressure on pleurodesis trials. Chest 2020; 157:249–250.
Chopra A, Judson MA, Doelken P, et al. The relationship of pleural manometry with postthoracentesis chest radiographic findings in malignant pleural effusion. Chest 2020; 157:421–426.
Martin GA, Tsim S, Kidd AC, et al. A randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis in malignant pleural effusion. Chest 2019; 156:1204–1213.
Lentz RJ, Lerner AD, Pannu JK, et al. Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial. Lancet Respir Med 2019; 7:447–455.
Matthews C, Freeman C, Sharples L, et al. MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial. BMJ Open Resp Res 2019; 6:e000368.
Mishra EK, Clive AO, Wills GH, et al. Randomised controlled trial of urokinase versus placebo for nondraining malignant pleural effusion. Am J Respir Crit Care Med 2018; 197:502–508.
Rintoul RC, Ritchie AJ, Edwards JG, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet 2014; 384:1118–1127.
Woolhouse I, Bishop L, Darlison L, et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax 2018; 73:i1–i30.
Crnjac A, Sok M, Kamenik M. Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma. Eur J Cardiothorac Surg 2004; 26:432–436.
Hojski A, Leitgeb M, Crnjac A. Release of growth factors after mechanical and chemical pleurodesis for treatment of malignant pleural effusion: a randomized control study. Radiol Oncol 2015; 49:386–394.
Clinical trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 29/02/2000. Identifier NCT04322136, AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion (AMPLE-3). Registered 29/5/2018 [cited 17/02/2020]; available from https://clinicaltrials.gov/ct2/show/record/NCT04322136.